Dallas, TX -- (SBWIRE) -- 02/06/2015 -- The report "Helicobacter Pylori Infections – Pipeline Review, H1 2015? provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections. Helicobacter pylori (H. pylori) are a bacterium that is commonly found in the stomach. The most common way of Helicobacter pylori infection is either oral-to-oral or fecal-to-oral contact. It is found in about two-thirds of the world's population. Helicobacter pylori cause peptic ulcers and stomach cancer. The infection is more common in packed living conditions with poor cleanliness.

Complete report is available
http://www.rnrmarketresearch.com/helicobacter-pylori-infections-pipeline-review-h1-2015-market-report.html

The report also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections and special features on late-stage and discontinued projects. Companies discussed in this Helicobacter Pylori Infections – Pipeline Review, H1 2015 report include Daewoong Pharmaceutical Co., Ltd., EpiVax, Inc., ImevaX GmbH, ImmunoBiology Ltd., RedHill Biopharma Ltd., Sequella, Inc., Shanghai Zerun Biotechnology Co., Ltd., Sigmoid Pharma Limited, Takeda Pharmaceutical Company Limited.

Signs or symptoms occur with Helicobacter pylori (H. pylori) infection includes an ache or burning pain in your abdomen, abdominal pain that's worse when your stomach is empty, nausea, loss of appetite, frequent burping, bloating and unintentional weight loss. Drug profiles discussed in this report includes rifabutin, amoxicillin sodium, omeprazole, DWJ-1325, H.pylori vaccine, helicobacter pylori infection vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine [Hel-305] (multivalent), HPi-1, IMX-101, Small Molecules for Helicobacter Pylori Infections, Small Molecules to Inhibit DNA Synthesis for Infectious Diseases, SQ-109, vonoprazan. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Order a Purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=269585

(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases

-Dec 26, 2014: New Drug Application Approval of TAKECAB for the treatment of Acid-related Diseases in Japan

-Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105

-Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA

-Dec 23, 2013: RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study

-Dec 17, 2013: RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection

-Dec 02, 2013: ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement on Development of Pharmaceutical Formulation for IMX101

-Oct 30, 2013: RedHill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection 64

Oct 22, 2013: RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 Phase III Study - to Commence Shortly

-Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers

Table of Content

List of Tables
Number of Products under Development for Helicobacter Pylori Infections, H1 2015
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Helicobacter Pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
Helicobacter Pylori Infections - Pipeline by EpiVax, Inc., H1 2015
Helicobacter Pylori Infections - Pipeline by ImevaX GmbH, H1 2015
Helicobacter Pylori Infections - Pipeline by ImmunoBiology Ltd., H1 2015
Helicobacter Pylori Infections - Pipeline by RedHill Biopharma Ltd., H1 2015
Helicobacter Pylori Infections - Pipeline by Sequella, Inc., H1 2015
Helicobacter Pylori Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H1 2015
Helicobacter Pylori Infections - Pipeline by Sigmoid Pharma Limited, H1 2015
Helicobacter Pylori Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Helicobacter Pylori Infections Therapeutics - Recent Pipeline Updates, H1 2015
Helicobacter Pylori Infections - Dormant Projects, H1 2015

Explore more reports on Infectious Diseases Therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics